Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival
Authors:
- Samer NaffoujeSNSamer Naffouje
- Shanel BhagwandinSBShanel Bhagwandin
- 1 December 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 25 (6) , 496-502
Abstract
Microphthalmia transcription factor (Mitf) is involved in melanocyte development and differentiation. We previously reported that Mitf expression, as detected by immunohistochemical analysis, is an independent prognostic marker in patients with intermediate-thickness melanoma. However, the clinical significance of Mitf expression in melanoma is not well delineated. In this prospective study, we attempted to demonstrate the correlation between Mitf expression in primary melanoma and the sentinel lymph node status and prognosis. We prospectively examined primary cutaneous melanomas from 94 patients undergoing nodal staging by sentinel lymph node biopsy. We quantified the percentage of tumor cells whose nuclei stained with the Mitf antibody visually. Survival curves were generated using the Kaplan–Meier method. The correlation between Mitf expression and nodal status was evaluated using the Mann–Whitney U-test. Here we demonstrate that Mitf expression is directly correlated with both disease-free survival (DFS) and overall survival (OS) over a median follow-up of 28.5 months. The mean DFS and OS in the eight patients whose melanomas did not stain positive for Mitf were 15.75±3.36 months (median, 12 months) and 38.17±5.18 months (median, 29 months), respectively. These results are significantly lower than those for patients who showed evidence of Mitf expression, in whom the mean DFS and OS were 66.1±4.03 months (median, not reached, P=0.0001) and 66.75±38.17 months (median, not reached, P=0.0001), respectively. The mean DFS and OS with greater than 25% (67 patients) of the melanoma cells staining positive for Mitf expression were 78.37±2.78 and 82.38±1.6 months, respectively, compared with 26.37±3.2 months (P=0.0001) and 44.53±4.5 months (P=0.0001), respectively, with up to 25% (27 patients) of cells stained positive for Mitf expression. In addition, there was a significant relationship between Mitf expression and nodal status, as evaluated by sentinel node biopsy. For example, none of the melanomas with greater than 50% Mitf expression had a positive sentinel node biopsy. Our study shows that expression of the molecular marker Mitf in primary cutaneous melanomas is a useful tool in assessing lymph node status. Mitf immunostaining in the primary tumor serves as a reliable predictor of occult lymph node metastases, as well as a favorable prognosticator of DFS and OS in melanoma patients.Keywords
This publication has 25 references indexed in Scilit:
- The New AJCC Guidelines in PracticeAmerican Journal of Surgical Pathology, 2013
- Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter DatabaseAnnals of Surgical Oncology, 2011
- Role of microphthalmia transcription factor (Mitf) in melanoma differentiationBiochemical and Biophysical Research Communications, 2007
- The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanomaCancer, 2006
- Predicting sentinel node status in AJCC stage I/II primary cutaneous melanomaCancer, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- A Nomogram That Predicts the Presence of Sentinel Node Metastasis in Melanoma With Better Discrimination Than the American Joint Committee on CancerStaging SystemAnnals of Surgical Oncology, 2005
- Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and functionBone, 2004
- Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes – one institution's experienceMelanoma Research, 2003
- Frozen Section Investigation of the Sentinel Node in Malignant Melanoma and Breast CancerAnnals of Surgical Oncology, 2001